Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth Q4 revenue slips 0.2% to $856.6 million; issues 2025 outlook

Mixed Impact 3 of 5 earnings Written later

AdaptHealth reported fourth-quarter and full-year 2024 results on February 25, 2025, and gave 2025 guidance. Fourth-quarter net revenue and adjusted EBITDA each fell slightly from the prior-year quarter, while full-year net revenue and adjusted EBITDA rose, and net income swung to a profit of $90.4 million from a loss of $678.9 million. The company's 2025 guidance calls for net revenue of $3.22 billion to $3.36 billion and adjusted EBITDA of $670 million to $710 million.

Key points

  • Q4 2024 net revenue was $856.6 million, down 0.2% from $858.2 million; Q4 adjusted EBITDA was $200.6 million, down 2.0%.
  • Full-year 2024 net revenue was $3.26 billion, up 1.9%, and adjusted EBITDA was $688.7 million, up 2.7%.
  • Full-year 2024 net income attributable to AdaptHealth was $90.4 million, compared with a loss of $678.9 million in 2023, which included an $830.8 million goodwill impairment.
  • 2025 guidance: net revenue of $3.22 billion to $3.36 billion, adjusted EBITDA of $670 million to $710 million, and free cash flow of $180 million to $220 million.

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECFeb 25, 2025, 7:11 AM ET
Accession number0001628280-25-007553

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.